People · Operator
Named in public records as an officer, director or promoter · active 2012–2018 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Velicept Therapeutics, Inc. | — | Pharmaceuticals | Series B | $39.9M | $204.0M | 2015 |
| Yaupon Therapeutics Inc | — | Pharmaceuticals | Series A | $21.6M | $256.8M | 2012 |
| Ralexar Therapeutics, Inc. | — | Pharmaceuticals | Series A | $19.0M | $132.5M | 2014 |
| Onspira Therapeutics, Inc. | — | Pharmaceuticals | Seed | $1.9M | $73.2M | 2017 |
Douglas Gessl at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Douglas Gessl on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Stephen Tullman | 4 | 7 |
| Kamil Ali-Jackson | 2 | 3 |
| Somu Subramaniam | 1 | 17 |
| David Hirsch | 1 | 16 |
| James Walker | 1 | 16 |
| Albert Cha | 1 | 9 |
| Neal Walker | 1 | 5 |
| James Huang | 1 | 5 |
| Somasundaram Subramaniam | 1 | 5 |
| Raju Mohan | 1 | 4 |
| Jason Hong | 1 | 4 |
| James C. Walker | 1 | 3 |
| Aidan King | 1 | 3 |
| Greg Vontz | 1 | 3 |
| Scott S. Morenstein | 1 | 3 |
| Scott Morenstein | 1 | 2 |
| John Doux | 1 | 2 |
| Thomas P. Hess | 1 | 2 |
| Paul Barone | 1 | 2 |
| Roy Levitt | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.